Interferon (unspecified)
What studies of interferon (unspecified) found
At a glance, by condition
Preventing long COVID: D Little or no difference
Based on the strongest evidence, compared with another group, not randomised (very low certainty): 3 findings, all D.
4 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies found little or no difference with interferon (unspecified) for preventing long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- CMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- Interferon (unspecified) · Preventing long COVID is hereDLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Preventing long COVID
Symptoms
Anxiety1 study · 231 people took interferon (unspecified) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people, or how many isn't reported.
Compared with another group, not randomised1 study · between 1–30 days or 1 day to anytime afterward (few people)
No clear difference in anxiety.
The evidence is very uncertain about the effect of interferon (unspecified) on anxiety later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- Few people, or how many isn't reported
See the 1 study
-
- People in the study
- —
- Dose
- —
- Outcome
- psychotic, mood, and anxiety disorders
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age at index, Race, Ethnicity, Sex, and COVID-19 status.
Age at index, Race, Ethnicity, Sex, and COVID-19 status.
- Selection of participants
- Moderate. comparison group: COVID-19 patients who were ≥18 years old without multiple sclerosis who did not receive IFN-α or -β treatment after diagnosis.
COVID-19 patients who were ≥18 years old without multiple sclerosis who did not receive IFN-α or -β treatment after diagnosis.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Patients with an outcome before the index event were excluded from calculations; per-arm numbers not analysed not reported.
If a patient had an outcome before the index event, they were excluded from calculations.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Breathlessness1 study · 231 people took interferon (unspecified) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people, or how many isn't reported.
Compared with another group, not randomised1 study · between 1–30 days or 1 day to anytime afterward (few people)
No clear difference in breathlessness.
The evidence is very uncertain about the effect of interferon (unspecified) on breathlessness later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- Few people, or how many isn't reported
See the 1 study
-
- People in the study
- —
- Dose
- —
- Outcome
- dyspnea
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age at index, Race, Ethnicity, Sex, and COVID-19 status.
Age at index, Race, Ethnicity, Sex, and COVID-19 status.
- Selection of participants
- Moderate. comparison group: COVID-19 patients who were ≥18 years old without multiple sclerosis who did not receive IFN-α or -β treatment after diagnosis.
COVID-19 patients who were ≥18 years old without multiple sclerosis who did not receive IFN-α or -β treatment after diagnosis.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Patients with an outcome before the index event were excluded from calculations; per-arm numbers not analysed not reported.
If a patient had an outcome before the index event, they were excluded from calculations.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Sleep1 study · 231 people took interferon (unspecified) Little or no difference D
Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); few people, or how many isn't reported.
Compared with another group, not randomised1 study · between 1–30 days or 1 day to anytime afterward (few people)
No clear difference in sleep.
The evidence is very uncertain about the effect of interferon (unspecified) on sleep later, when given during acute COVID. Little or no difference · very low certainty D
- Serious risk of bias (ROBINS-I)
- Few people, or how many isn't reported
See the 1 study
-
- People in the study
- —
- Dose
- —
- Outcome
- insomnia
- Effect
- no clear difference
- Risk of bias
ROBINS-I: Serious
- Confounding
- Moderate. adjusted for: Age at index, Race, Ethnicity, Sex, and COVID-19 status.
Age at index, Race, Ethnicity, Sex, and COVID-19 status.
- Selection of participants
- Moderate. comparison group: COVID-19 patients who were ≥18 years old without multiple sclerosis who did not receive IFN-α or -β treatment after diagnosis.
COVID-19 patients who were ≥18 years old without multiple sclerosis who did not receive IFN-α or -β treatment after diagnosis.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Patients with an outcome before the index event were excluded from calculations; per-arm numbers not analysed not reported.
If a patient had an outcome before the index event, they were excluded from calculations.
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Daily life and health overall
Overall symptoms1 study · 231 people took interferon (unspecified) Uncertain –
Why this grade: Uncertain, very low certainty, from controlled studies: risk of bias couldn't be judged for most results (ROBINS-I: no information); few people, or how many isn't reported; not all results were tested against chance; one study saw it get worse, without a test against chance.
Compared with another group, not randomised1 study · between 1–30 days or 1 day to anytime afterward (few people)
Too little to say about overall symptoms.
Too little to say: overall symptoms got worse in one study, but the change wasn't tested against chance. Uncertain · very low certainty –
- Risk of bias couldn't be judged for most results (ROBINS-I: no information)
- Few people, or how many isn't reported
- Not all results were tested against chance
- One study saw it get worse, without a test against chance
See the 1 study
-
- People in the study
- —
- Dose
- —
- Outcome
- death
- Effect
- worse (not tested)
- Risk of bias
ROBINS-I: No information
- Confounding
- Moderate. adjusted for: Age at index, Race, Ethnicity, Sex, and COVID-19 status.
Age at index, Race, Ethnicity, Sex, and COVID-19 status.
- Selection of participants
- Moderate. comparison group: COVID-19 patients who were ≥18 years old without multiple sclerosis who did not receive IFN-α or -β treatment after diagnosis.
COVID-19 patients who were ≥18 years old without multiple sclerosis who did not receive IFN-α or -β treatment after diagnosis.
- Classification of interventions
- Moderate. from records after the fact
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- Moderate. missing data: Patients with an outcome before the index event were excluded from calculations; per-arm numbers not analysed not reported.
If a patient had an outcome before the index event, they were excluded from calculations.
- Measurement of outcomes
- Low. an objective measure
- Selection of the reported result
- NI. whether this outcome was pre-specified isn't reported
Side effects
No study of this treatment alone reported side effects we could read.
All papers
- Evaluation of Type I Interferon Treatment in Hospitalized COVID-19 Patients: A Retrospective Cohort Study.2024 · compared with another group
- Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review.2006 · systematic review
Summary
This updated systematic review asked whether any intervention is effective for treatment, management or rehabilitation of adults and children with CFS/ME. The authors searched eleven electronic databases and included 70 studies, of which 59 were RCTs; comparisons were between treatment and control groups. Interventions included CBT, GET, rehabilitation, immunological and pharmacological treatments, supplements and complementary therapies. Outcomes covered physical, psychological, laboratory/physiological and quality-of-life measures. CBT and GET appeared to reduce symptoms and improve function based on RCTs. In a CBT trial (n=69), physical functioning, fatigue and symptoms favoured CBT (P<0.003) and school attendance favoured treatment (P=0.04). Another CBT trial (n=65) found no significant difference for fatigue, anxiety and depression, or disability. In GET trials, CGI and fatigue favoured treatment (n=49; P<0.03), and fatigue and depression/anxiety were significantly better (n=61; P=0.027). One GET trial reported withdrawal of one patient in each group because of worsening symptoms; eleven patients withdrew because of adverse events in a GET with or without fluoxetine trial. Galantamine (n=434) showed no significant differences; 130 patients withdrew, 389 reported adverse events and 88 withdrew. Acetyl-L-carnitine and propionyl-L-carnitine (n=90) improved general fatigue in PLC (P=0.004) and combined group (P<0.001), and mental fatigue in ALC group (P=0.015); 8 patients withdrew due to side effects. Staphylococcus toxoid (n=98) had 13 treatment-group and 7 placebo-group patients with side effects. Hydrocortisone/fludrocortisone (n=80) found no significant differences.
- Interventions for the treatment and management of chronic fatigue syndrome: a systematic review.2001 · systematic review
Summary
This systematic review asked whether interventions for chronic fatigue syndrome (CFS) work. Nineteen specialist databases were searched, and 44 trials met inclusion criteria: 36 randomized controlled trials and 8 controlled trials. Treatments were grouped by type and compared with control conditions. Outcomes were classified as positive, negative, or no effect. Three randomized controlled trials of GET all showed an overall beneficial effect compared with control groups. Three of four randomized controlled trials of CBT found a positive overall effect; one controlled trial did not find overall beneficial effects. One randomized controlled trial found no effect of fluoxetine either alone or with GET. Hydrocortisone showed an overall beneficial effect in one randomized controlled trial and some beneficial effects in another. For immunoglobulin, two randomized controlled trials showed an overall beneficial effect, two showed some positive effects, and the largest reported no effect. Acyclovir showed a negative effect for one outcome. Randomized controlled trials of fludrocortisone, antidepressants, moclobemide, sulbutiamine, growth hormone and galanthamine hydrobromide found no effects. Oral NADH showed an overall beneficial effect in one randomized controlled trial. Harms included withdrawals from immunoglobulin therapy (2 due to severe constitutional symptoms, 1 due to a skin eruption, 1 due to mild but transient liver failure, 1 due to phlebitis, and 2 whose adverse effects were not reported), 3 withdrawals from acyclovir due to reversible renal failure, and 2 participants leaving the magnesium group after a generalized rash. CBT trials had a dropout rate of 19% (114/589), GET trials 18% (68/370), and pharmacological trials 11% (99/869).